The serum PSA and PAP were measured in 23 cases of prostatic carcinoma

42 cases of benign prostatic hypertrophy and 21 cases of non-prostatic disease. Significant differences had been found between prostatic carcinoma and benign prostatic hypertrophy or control group. According to the Decision Matrix for general clinical evaluation. The diagnostic index and availability of serum PSA and PAP were 135.8%

138.3% and 0.36

0.40

respectively. The study showed that the measurement of the serum PSA and PAP should be complementary each other for the diagnosis and differential diagnosis of prostatic carcinoma. Finally

it was considered that the measurement of the serum PSA is superior to that of PAP for therapeutic follow- up in patients with prostatic carcinoma.